1. A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Issue 2 (1st February 2023) Authors: Palomba, M Lia; Ghione, Paola; Patel, Anik R; Nahas, Myrna; Beygi, Sara; Hatswell, Anthony J; Kanters, Steve; Limbrick-Oldfield, Eve H.; Wade, Sally W; Ray, Markqayne D; Owen, Jessica; Neelapu, Sattva S; Gribben, John; Radford, John; Bobillo, Sabela Journal: Expert review of anticancer therapy Issue: Volume 23:Issue 2(2023) Page Start: 199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience. Issue 2 (16th February 2022) Authors: Palomba, M Lia; Qualls, David; Monette, Sebastien; Sethi, Shenon; Dogan, Ahmet; Roshal, Mikhail; Senechal, Brigitte; Wang, Xiuyan; Rivière, Isabelle; Sadelain, Michel; Brentjens, Renier J; Park, Jae H; Smith, Eric L Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 2(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Issue 11 (November 2020) Authors: Castillo, Jorge J; Advani, Ranjana H; Branagan, Andrew R; Buske, Christian; Dimopoulos, Meletios A; D'Sa, Shirley; Kersten, Marie José; Leblond, Veronique; Minnema, Monique C; Owen, Roger G; Palomba, M Lia; Talaulikar, Dipti; Tedeschi, Alessandra; Trotman, Judith; Varettoni, Marzia; Vos, Josephin... Journal: Lancet Issue: Volume 7:Issue 11(2020) Page Start: e827 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Issue 10254 (19th September 2020) Authors: Abramson, Jeremy S; Palomba, M Lia; Gordon, Leo I; Lunning, Matthew A; Wang, Michael; Arnason, Jon; Mehta, Amitkumar; Purev, Enkhtsetseg; Maloney, David G; Andreadis, Charalambos; Sehgal, Alison; Solomon, Scott R; Ghosh, Nilanjan; Albertson, Tina M; Garcia, Jacob; Kostic, Ana; Mallaney, Mary; Oga... Journal: Lancet Issue: Volume 396:Issue 10254(2020) Page Start: 839 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Issue 3 (March 2015) Authors: Moskowitz, Alison J; Schöder, Heiko; Yahalom, Joachim; McCall, Susan J; Fox, Stephanie Y; Gerecitano, John; Grewal, Ravinder; Hamlin, Paul A; Horwitz, Steven; Kobos, Rachel; Kumar, Anita; Matasar, Matthew; Noy, Ariela; Palomba, M Lia; Perales, Miguel-Angel; Portlock, Carol S; Sauter, Craig; Shukl... Journal: Lancet oncology Issue: Volume 16:Issue 3(2015:Mar.) Page Start: 284 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Issue 3 (March 2015) Authors: Moskowitz, Alison J; Schöder, Heiko; Yahalom, Joachim; McCall, Susan J; Fox, Stephanie Y; Gerecitano, John; Grewal, Ravinder; Hamlin, Paul A; Horwitz, Steven; Kobos, Rachel; Kumar, Anita; Matasar, Matthew; Noy, Ariela; Palomba, M Lia; Perales, Miguel-Angel; Portlock, Carol S; Sauter, Craig; Shukl... Journal: Lancet oncology Issue: Volume 16:Issue 3(2015:Mar.) Page Start: 284 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Issue 10277 (6th March 2021) Authors: Mato, Anthony R; Shah, Nirav N; Jurczak, Wojciech; Cheah, Chan Y; Pagel, John M; Woyach, Jennifer A; Fakhri, Bita; Eyre, Toby A; Lamanna, Nicole; Patel, Manish R; Alencar, Alvaro; Lech-Maranda, Ewa; Wierda, William G; Coombs, Catherine C; Gerson, James N; Ghia, Paolo; Le Gouill, Steven; Lewis, Da... Journal: Lancet Issue: Volume 397:Issue 10277(2021) Page Start: 892 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. (27th April 2018) Authors: Varughese, Tilly; Taur, Ying; Cohen, Nina; Palomba, M Lia; Seo, Susan K; Hohl, Tobias M; Redelman-Sidi, Gil Journal: Clinical infectious diseases Issue: Volume 67:Number 5(2018) Page Start: 687 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Issue 12 (December 2021) Authors: Soumerai, Jacob D; Mato, Anthony R; Dogan, Ahmet; Seshan, Venkatraman E; Joffe, Erel; Flaherty, Kelsey; Carter, Jason; Hochberg, Ephraim; Barnes, Jeffrey A; Hamilton, Audrey M; Abramson, Jeremy S; Batlevi, Connie L; Matasar, Matthew J; Noy, Ariela; Owens, Colette N; Palomba, M Lia; Kumar, Anita; ... Journal: Lancet Issue: Volume 8:Issue 12(2021) Page Start: e879 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗